pdufa.bio

Topical Roflumilast

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

Topical Roflumilast is an Arcutis Biotherapeutics Inc. program. Every date links its source.

ARQT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Arcutis Biotherapeutics Inc. (ARQT). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Sep 2026ARQT

Specialist biotech funds holding ARQT, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors2,042,000$53.5 millionfiled August 14, 2026
Cormorant Asset Management175,000$4.6 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Topical Roflumilast's next FDA decision or readout?

No upcoming catalyst is on our calendar for Topical Roflumilast; no FDA decisions are on record below.

What happened at Topical Roflumilast's most recent FDA decision?

No FDA decision for Topical Roflumilast is in our archive yet.

Who makes Topical Roflumilast?

Arcutis Biotherapeutics Inc. (ARQT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.